コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 PANVAC) or PANVAC with per injection GM-CSF (granulocyte-macrophage colony-stimulating factor).
2 at activate innate immunity (eg, recombinant granulocyte-macrophage colony-stimulating factor).
3 -1(-) fraction and produced IL-22, IL-8, and granulocyte macrophage colony stimulating factor.
4 L-8, vascular endothelial growth factor, and granulocyte macrophage colony-stimulating factor.
5 ared with all other treatments except CTLA-4/granulocyte macrophage colony-stimulating factor.
6 ma levels of tumor necrosis factor-alpha and granulocyte macrophage colony-stimulating factor.
7 ) ligand 1 and (C-C motif) ligand 2, and the granulocyte macrophage colony-stimulating factor.
8 etic cytokines interleukin (IL)-6, IL-7, and granulocyte macrophage-colony-stimulating factor.
9 XCR7, CXCL1, CXCL8, CCL2, interleukin-6, and granulocyte-macrophage colony stimulating factor.
10 n disease pathogenesis and possibly also for granulocyte-macrophage colony-stimulating factor.
11 the presence of inflammatory signals such as granulocyte-macrophage colony-stimulating factor.
12 l meningitis had autoantibodies only against granulocyte-macrophage colony-stimulating factor.
13 ins it shares with binding sites of IL-3 and granulocyte-macrophage colony-stimulating factor.
14 n pattern-recognition receptors, and produce granulocyte-macrophage colony-stimulating factor.
15 ted defect in innate immune responses toward granulocyte-macrophage colony-stimulating factor.
16 oduction of IL-10 and enhanced production of granulocyte-macrophage colony-stimulating factor.
17 multiple myeloma fusions in conjunction with granulocyte-macrophage colony-stimulating factor.
18 nditioned to an alveolar-like phenotype with granulocyte-macrophage colony-stimulating factor.
19 V group had further enhancement of IL-10 and granulocyte-macrophage colony-stimulating factor.
20 tigen-1 and acquisition of responsiveness to granulocyte-macrophage colony-stimulating factor.
21 marked production of IFN-gamma, IL-17A, and granulocyte-macrophage colony-stimulating factor.
22 eron gamma, tumor necrosis factor alpha, and granulocyte-macrophage colony-stimulating factor.
23 ns, over 2 weeks) to one metastatic site and granulocyte-macrophage colony-stimulating factor (125 mu
24 day or 25 mg/m(2) per day) on days 2-5 plus granulocyte macrophage colony-stimulating factor (250 mu
25 -23.5% (95% CI -12.4, -33.2 [P = 0.004]) for granulocyte-macrophage colony-stimulating factor, -33.4%
26 were randomized to receive human recombinant granulocyte-macrophage colony stimulating factor (64 sub
27 adermal vaccinations of IMA901 (4.13 mg) and granulocyte macrophage colony-stimulating factor (75 mug
29 xin, macrophage colony-stimulating factor or granulocyte-macrophage colony-stimulating factor, all of
30 o the splenic red pulp, where they encounter granulocyte macrophage colony-stimulating factor and int
31 ted into CD11b(+)Gr1(+) MDSCs in vitro under granulocyte macrophage colony-stimulating factor and int
32 dent reduction in expression of the cytokine granulocyte macrophage colony-stimulating factor and the
33 or iNOS mice and cultured in the presence of granulocyte-macrophage colony-stimulating factor and hep
34 dy-mediated cell enrichment, and cultured in granulocyte-macrophage colony-stimulating factor and int
35 in the absence of the prosurvival cytokines granulocyte-macrophage colony-stimulating factor and int
36 monocyte chemotactic protein-1, and reduced granulocyte-macrophage colony-stimulating factor and mac
37 CD cases analyzed) had reduced responses to granulocyte-macrophage colony-stimulating factor and mar
38 L2, CCL4, and CXCL10; and the growth factors granulocyte-macrophage colony-stimulating factor and pla
39 constitutively produce human interleukin-3, granulocyte-macrophage colony-stimulating factor and Ste
40 (+) DCs acquired high langerin and CD1a with granulocyte-macrophage colony-stimulating factor and tra
41 wild-type MEFs, RP3 upregulated CCL2, CXCL1, granulocyte-macrophage colony-stimulating factor and tum
42 iopsies and led to a correlative decrease in granulocyte-macrophage colony-stimulating factor and whi
43 macrophage inflammatory protein (MIP)-1beta, granulocyte macrophage colony-stimulating factor) and ad
44 alpha, interleukin-1beta, interleukin-6, and granulocyte macrophage colony-stimulating factor) and hy
45 e evasion superfamily, to antagonize GM-CSF (granulocyte macrophage colony-stimulating factor) and IL
46 V secretomes including interleukin-6 (IL-6), granulocyte macrophage colony-stimulating factor, and IL
47 tissue, including growth-regulated oncogene, granulocyte macrophage colony-stimulating factor, and IL
48 ctor, granulocyte colony-stimulating factor, granulocyte macrophage colony-stimulating factor, and ma
49 -1alpha, MIP-1beta), hematopoietic IL-7, and granulocyte macrophage colony-stimulating factor, and re
50 IL-6, granulocyte-colony stimulating factor, granulocyte-macrophage colony-stimulating factor, and C-
51 a, interferon-gamma-inducible 10-kd protein, granulocyte-macrophage colony-stimulating factor, and CR
52 terferon gamma, tumor necrosis factor alpha, granulocyte-macrophage colony-stimulating factor, and gr
53 phage inflammatory protein 1alpha and 1beta, granulocyte-macrophage colony-stimulating factor, and in
54 train that expressed human stem cell factor, granulocyte-macrophage colony-stimulating factor, and in
55 rleukin-9, interleukin-15, interferon-gamma, granulocyte-macrophage colony-stimulating factor, and mo
56 L]13, CCL26, chemokine C-X-C motif ligand 5, granulocyte-macrophage colony-stimulating factor, and th
57 press more interleukin 17, interferon gamma, granulocyte-macrophage colony-stimulating factor, and tu
58 tent myeloid progenitors with a high dose of granulocyte-macrophage colony-stimulating factor; and (i
59 is factor (TNF)-alpha, interferon-gamma, and granulocyte-macrophage colony-stimulating factor] and ni
61 ls displayed higher levels of immunoreactive granulocyte-macrophage colony-stimulating factor as well
62 g), immature autologous dendritic cells, and granulocyte-macrophage colony-stimulating factor at the
63 sseminated nontuberculous mycobacteria; anti-granulocyte macrophage colony-stimulating factor autoant
64 e colony-stimulating factor receptor or anti-granulocyte-macrophage colony-stimulating factor autoant
65 ardial AT and performed B-cell depletion and granulocyte-macrophage colony-stimulating factor blockad
66 and dendritic cells (DCs) when cultured with granulocyte macrophage-colony-stimulating factor but not
67 production of the chemokines CCL2, CCL5, and granulocyte-macrophage colony-stimulating factor by gast
68 kines (IL-2, IL-12, IL-17, gamma interferon, granulocyte-macrophage colony-stimulating factor) by CD4
69 hoic acid, peptidoglycan, dexamethasone, and granulocyte-macrophage colony stimulating factor, by dri
70 vity and expression of the interleukin 3 and granulocyte/macrophage-colony stimulating factor common
71 RB had reduced pSTAT5 after stimulation with granulocyte-macrophage colony-stimulating factor, compar
72 s (granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor), consi
73 ificantly increased the expression levels of granulocyte-macrophage colony-stimulating factor (CSF),
74 ted expression of Il17a, Csf2 (which encodes granulocyte-macrophage colony-stimulating factor), Cxcl1
75 3 induced secretion of interleukin-6 (IL-6), granulocyte-macrophage colony-stimulating factor, CXCL8,
76 fects on YFP expression, cell viability, and granulocyte macrophage colony-stimulating factor-depende
77 tial are mobilized into the bloodstream by a granulocyte-macrophage colony-stimulating factor-depende
78 Granulocyte-macrophage colony-stimulating factor-derived
79 Mixed chimeric mice lacking B cell-derived granulocyte macrophage colony-stimulating factor develop
80 ctor-differentiated macrophages more than in granulocyte-macrophage colony-stimulating factor-differe
82 ndromic sequence TGTGGCTGCCCACA in the human granulocyte macrophage colony-stimulating factor enhance
83 This study revealed increased granulocyte-macrophage colony-stimulating factor express
84 ting both in vivo and in vitro evaluation of granulocyte-macrophage colony-stimulating factor express
85 ination with GVAX vaccination (consisting of granulocyte macrophage colony-stimulating factor-express
87 ng: tumor necrosis factor alpha (TNF-alpha), granulocyte macrophage colony stimulating factor (GM-CSF
88 cancer subjects treated with Ipilimumab and granulocyte macrophage colony stimulating factor (GM-CSF
89 anulocyte colony stimulating factor (G-CSF), granulocyte macrophage colony stimulating factor (GM-CSF
90 pled to keyhole limpet hemocyanin (KLH) plus granulocyte macrophage colony-stimulating factor (GM-CSF
91 nocyte-derived macrophages (MDMs), including granulocyte macrophage colony-stimulating factor (GM-CSF
92 enhances production of the potent chemokine granulocyte macrophage colony-stimulating factor (GM-CSF
93 ates and presenting distinct combinations of granulocyte macrophage colony-stimulating factor (GM-CSF
94 time and continuous action of both FLT3L and granulocyte macrophage colony-stimulating factor (GM-CSF
95 erative capacity, constitutive activation of granulocyte macrophage colony-stimulating factor (GM-CSF
96 eptor gamma-t (RORgammat), IL-17, IL-22, and granulocyte macrophage colony-stimulating factor (GM-CSF
97 n = 3 donors] with PSC supernatants or IL-6/granulocyte macrophage colony-stimulating factor (GM-CSF
99 rophage colony-stimulating factor (M-CSF) or granulocyte macrophage colony-stimulating factor (GM-CSF
100 in the dLN is due to the local production of granulocyte macrophage colony-stimulating factor (GM-CSF
101 that induce antimicrobial activity, such as granulocyte macrophage colony-stimulating factor (GM-CSF
103 tumor to peripheral compartments showed that granulocyte macrophage colony-stimulating factor (GM-CSF
105 ination with irradiated B16 tumor expressing granulocyte macrophage colony-stimulating factor (GM-CSF
107 linical models, combining CTLA4 blockade and granulocyte macrophage colony-stimulating factor (GM-CSF
108 genitors after coculture with breast cancer: granulocyte macrophage colony-stimulating factor (GM-CSF
109 and clinical studies have demonstrated that granulocyte macrophage colony-stimulating factor (GM-CSF
110 In this context, interleukin 4 (IL-4) and granulocyte macrophage colony-stimulating factor (GM-CSF
111 cial effectors of the interleukin-23 (IL-23)-granulocyte macrophage colony-stimulating factor (GM-CSF
112 langerin, when cultured with soluble ligands granulocyte macrophage colony-stimulating factor (GM-CSF
113 ectively replicate within tumors and produce granulocyte macrophage colony-stimulating factor (GM-CSF
114 d PuraMatrix(TM) peptide hydrogel containing granulocyte macrophage colony-stimulating factor (GM-CSF
116 ency virus-uninfected adults, including anti-granulocyte macrophage colony-stimulating factor (GM-CSF
118 evidence indicates that specific cytokines, granulocyte macrophage colony-stimulating factors (GM-CS
120 tivity by clonal myeloid progenitor cells to granulocyte macrophage-colony stimulating factor (GM-CSF
121 edullary hematopoiesis was also evident, and granulocyte macrophage-colony stimulating factor (GM-CSF
123 ILC-driven colitis depends on production of granulocyte macrophage-colony stimulating factor (GM-CSF
125 MML), demonstrating that mutant Shp2 induces granulocyte macrophage-colony-stimulating factor (GM-CSF
126 ne kinase-3(Flt3) ligand-induced, but not in granulocyte macrophage-colony-stimulating factor (GM-CSF
127 corrects gain-of-function (GOF) Shp2-induced granulocyte macrophage-colony-stimulating factor (GM-CSF
128 d vascular endothelial growth factor but not granulocyte macrophage-colony-stimulating factor (GM-CSF
130 selective hypersensitivity of JMML cells to granulocyte macrophage-colony-stimulating factor (GM-CSF
131 the cytokines interleukin (IL)-3, IL-5, and granulocyte macrophage-colony-stimulating factor (GM-CSF
132 E must produce the pro-inflammatory cytokine granulocyte-macrophage colony stimulating factor (GM-CSF
134 odeficiency virus (SIV) vaccine coexpressing granulocyte-macrophage colony stimulating factor (GM-CSF
135 CMML cells is identified to display aberrant granulocyte-macrophage colony stimulating factor (GM-CSF
136 autologous tumor cells engineered to secrete granulocyte-macrophage colony stimulating factor (GM-CSF
138 we show that, compared with other cytokines [granulocyte-macrophage colony stimulating factor (GM-CSF
139 microbiota enhances respiratory defenses via granulocyte-macrophage colony-stimulating factor (GM-CSF
143 ulating production of the chemokine CCL2 and granulocyte-macrophage colony-stimulating factor (GM-CSF
144 een shown to be dependent on TH cell-derived granulocyte-macrophage colony-stimulating factor (GM-CSF
145 D, matrix metalloproteinase (MMP)-9, IL-1Ra, granulocyte-macrophage colony-stimulating factor (GM-CSF
146 an intradermal lower abdominal injection of granulocyte-macrophage colony-stimulating factor (GM-CSF
147 by incubation of human blood monocytes with granulocyte-macrophage colony-stimulating factor (GM-CSF
148 tiated into iDCs by interleukin-4 (IL-4) and granulocyte-macrophage colony-stimulating factor (GM-CSF
149 ecent studies highlight surprising roles for granulocyte-macrophage colony-stimulating factor (GM-CSF
150 ion of DCs through injection of WT mice with granulocyte-macrophage colony-stimulating factor (GM-CSF
151 anulocyte colony-stimulating factor (G-CSF), granulocyte-macrophage colony-stimulating factor (GM-CSF
153 monary alveolar proteinosis (hPAP) caused by granulocyte-macrophage colony-stimulating factor (GM-CSF
154 1alpha, MIP-1alphaP (CCL3L1), and MIP-1beta; granulocyte-macrophage colony-stimulating factor (GM-CSF
156 sed production of interleukin 12 (IL-12) and granulocyte-macrophage colony-stimulating factor (GM-CSF
157 teinosis is caused by autoantibodies against granulocyte-macrophage colony-stimulating factor (GM-CSF
158 nes/cytokines such as CCL-3 (MIP-1alpha) and granulocyte-macrophage colony-stimulating factor (GM-CSF
159 17), gamma interferon (IFN-gamma), CCL4, and granulocyte-macrophage colony-stimulating factor (GM-CSF
161 MML) is characterized by hypersensitivity to granulocyte-macrophage colony-stimulating factor (GM-CSF
163 via STAT3 and Bim, and this was inhibited by granulocyte-macrophage colony-stimulating factor (GM-CSF
164 tes of rs1059513 had increased TNF-alpha and Granulocyte-macrophage colony-stimulating factor (GM-CSF
165 ate into DCs, which were more efficient than granulocyte-macrophage colony-stimulating factor (GM-CSF
166 GD2 monoclonal antibody (MoAb) combined with granulocyte-macrophage colony-stimulating factor (GM-CSF
167 tic Ad co-expressing interleukin (IL)-12 and granulocyte-macrophage colony-stimulating factor (GM-CSF
168 use model of PDA, we show that tumor-derived granulocyte-macrophage colony-stimulating factor (GM-CSF
170 erapy using anti-GD2 monoclonal antibody and granulocyte-macrophage colony-stimulating factor (GM-CSF
171 d progenitors and, when treated ex vivo with granulocyte-macrophage colony-stimulating factor (GM-CSF
173 hat IL-23 induced production of the cytokine granulocyte-macrophage colony-stimulating factor (GM-CSF
175 hat was superior to that of vaccination with granulocyte-macrophage colony-stimulating factor (GM-CSF
176 ved that monocytes treated with the cytokine granulocyte-macrophage colony-stimulating factor (GM-CSF
178 otherapy-induced lymphodepletion followed by granulocyte-macrophage colony-stimulating factor (GM-CSF
179 necrosis factor (TNF) induces expression of granulocyte-macrophage colony-stimulating factor (GM-CSF
180 ty is enhanced when ch14.18 is combined with granulocyte-macrophage colony-stimulating factor (GM-CSF
181 cruitment and/or activation molecules, e.g., granulocyte-macrophage colony-stimulating factor (GM-CSF
182 ation of Lin(Neg) marrow cells cultured with granulocyte-macrophage colony-stimulating factor (GM-CSF
183 leukin-2 (IL-2), and interferon alfa-2b with granulocyte-macrophage colony-stimulating factor (GM-CSF
184 l groups received vehicle, dexamethasone, or granulocyte-macrophage colony-stimulating factor (GM-CSF
185 ia, and a characteristic hypersensitivity to granulocyte-macrophage colony-stimulating factor (GM-CSF
186 rved elevation of CCL2, CCL5, CXCL1, CXCL10, granulocyte-macrophage colony-stimulating factor (GM-CSF
188 rial to assess the efficacy of JS1/34.5-/47-/granulocyte-macrophage colony-stimulating factor (GM-CSF
189 erleukin-6, tumor necrosis factor alpha, and granulocyte-macrophage colony-stimulating factor (GM-CSF
190 Neutralizing autoantibodies (Ab) against granulocyte-macrophage colony-stimulating factor (GM-CSF
191 BAFF and other key signaling pathways, i.e., granulocyte-macrophage colony-stimulating factor (GM-CSF
193 infected rats and mice showed low levels of granulocyte-macrophage colony-stimulating factor (GM-CSF
194 ced by the presence of eosinophil-activating granulocyte-macrophage colony-stimulating factor (GM-CSF
195 the second and fourth courses of ch14.18 and granulocyte-macrophage colony-stimulating factor (GM-CSF
198 chanistic studies suggest that the increased granulocyte-macrophage colony-stimulating factor (GM-CSF
199 PPAR-gamma), which is induced by exposure to granulocyte-macrophage colony-stimulating factor (GM-CSF
200 omyelitis and had reduced productions of the granulocyte-macrophage colony-stimulating factor (GM-CSF
201 production of the pro-inflammatory cytokine granulocyte-macrophage colony-stimulating factor (GM-CSF
203 activity during SAA treatment or blockade of granulocyte-macrophage colony-stimulating factor (GM-CSF
204 s study, we tested the hypotheses that human granulocyte-macrophage colony-stimulating factor (GM-CSF
205 njections of neutralizing antibodies against granulocyte-macrophage colony-stimulating factor (GM-CSF
206 al M1-like MO, we tested the pro-M1 cytokine granulocyte-macrophage colony-stimulating factor (GM-CSF
208 f MDSCs, generated from bone marrow cells by granulocyte-macrophage colony-stimulating factor (GM-CSF
209 es in Th1 cytokines such as IL-2, IL-15, and granulocyte-macrophage colony-stimulating factor (GM-CSF
210 ulture of murine bone marrow (BM) cells with granulocyte-macrophage colony-stimulating factor (GM-CSF
211 o-controlled trial to evaluate the effect of granulocyte-macrophage colony-stimulating factor (GM-CSF
215 which controls IgM production via autocrine granulocyte/macrophage colony-stimulating factor (GM-CSF
216 ar proteinosis (PAP) syndrome, disruption of granulocyte/macrophage colony-stimulating factor (GM-CSF
217 human and mouse cardiac fibroblasts produce granulocyte/macrophage colony-stimulating factor (GM-CSF
219 d bone marrow cells were cultured with mouse granulocyte/macrophage colony-stimulating factor (GM-CSF
220 n [CAWS]), we identify an essential role for granulocyte/macrophage colony-stimulating factor (GM-CSF
221 m bone marrow progenitors in the presence of granulocyte/macrophage colony-stimulating factor (GM-CSF
224 nterleukin-2 [IL-2]) and -independent (IL-6, granulocyte-macrophage colony-stimulating factor [GM-CSF
225 gamma], interleukin 10 [IL-10], IL-13, IL-6, granulocyte-macrophage colony-stimulating factor [GM-CSF
226 on of host genes coding for proinflammatory (granulocyte-macrophage colony-stimulating factor [GM-CSF
227 cell factor [SCF], Flt-3/Flk-2 ligand [FL], granulocyte/macrophage-colony stimulating factor [GM-CSF
228 nal concentrations than controls (n = 42) of granulocyte-macrophage colony-stimulating factor [(GM-CS
229 10, IL-12(p70), IL-13, TNF-alpha, IFN-gamma, granulocyte-macrophage colony-stimulating factor, granul
230 nsfectants, including genes for pentraxin 3, granulocyte-macrophage colony-stimulating factor, granul
231 Stat3 rescues activating mutant Shp2-induced granulocyte-macrophage colony-stimulating factor hyperse
232 okines (eg, IL-17A, IL-22, interferon-gamma, granulocyte macrophage colony-stimulating factor, IL-13)
233 sue, inflammation increased the secretion of granulocyte macrophage-colony stimulating factor, IL-12,
234 septic shock, whereas vasopressin decreased granulocyte-macrophage colony-stimulating factor in pati
235 Granulocyte-macrophage colony-stimulating factor induced
236 l factor induced LHPC proliferation, whereas granulocyte-macrophage-colony stimulating factor induced
237 moral delivery of interleukin-12 (IL-12) and granulocyte macrophage colony-stimulating factor induces
238 f numerous cytokines and chemokines, such as granulocyte macrophage colony-stimulating factor, interf
239 resulting in degranulation and secretion of granulocyte-macrophage colony-stimulating factor, interf
240 High levels of serum cytokines (granulocyte macrophage colony-stimulating factor, interl
241 retory levels of various cytokines including granulocyte-macrophage colony-stimulating factor, interl
242 sis in the lungs, constitutive expression of granulocyte-macrophage colony-stimulating factor, interl
243 This DC subset was stimulated with granulocyte-macrophage colony-stimulating factor, interl
244 rom adherent mononuclear cells cultured with granulocyte-macrophage colony-stimulating factor, interl
245 terleukin-6, interleukin-10, interleukin-17, granulocyte-macrophage colony-stimulating factor, interl
246 activation of the common beta subunit of the granulocyte-macrophage colony-stimulating factor/interle
252 viruses were successfully armed with murine granulocyte-macrophage colony-stimulating factor (mGM-CS
253 required to determine whether treatment with granulocyte-macrophage colony stimulating factor might a
254 pro-immunogenic effects of radiotherapy with granulocyte-macrophage colony-stimulating factor might r
255 Interleukin-4, interleukin-8, granulocyte macrophage colony-stimulating factor, monocy
256 ncrease in serum interleukin (IL) -2, IL-15, granulocyte-macrophage colony-stimulating factor, natura
257 B-cell depletion or granulocyte-macrophage colony-stimulating factor neutral
258 e have demonstrated that, when cultured with granulocyte macrophage-colony-stimulating factor, neutro
259 10-11 after vaccination; and peak levels of granulocyte-macrophage-colony-stimulating factor on days
260 onsisting of irradiated ID8 cells expressing granulocyte macrophage colony-stimulating factor or FLT3
262 nts were allocated (2:1) to PROSTVAC-VF plus granulocyte-macrophage colony-stimulating factor or to c
263 23% in placebo vs. 17% in patients receiving granulocyte-macrophage colony stimulating factor (p = .3
264 hemokine (C-C motif) ligand 5 (P < 0.01) and granulocyte-macrophage colony-stimulating factor (P < 0.
265 +/- 11.3 days placebo vs. 15.7 +/- 11.9 days granulocyte-macrophage colony stimulating factor, p = .1
266 +/- 10.3 days placebo vs. 10.8 +/- 10.5 days granulocyte-macrophage colony stimulating factor, p = .8
267 The combination of radiotherapy with granulocyte-macrophage colony-stimulating factor produce
268 Granulocyte macrophage colony-stimulating factor-produci
269 l clusters and 3-fold upregulated numbers of granulocyte-macrophage colony-stimulating factor-produci
270 nesis of preeclampsia, markedly up-regulated granulocyte-macrophage colony-stimulating factor product
271 related markers interferon-gamma, IL-15, and granulocyte-macrophage colony-stimulating factor protect
272 rs of this mutation had reduced responses to granulocyte-macrophage colony-stimulating factor, provid
273 ifferentiation genes, such as macrophage and granulocyte macrophage colony-stimulating factor recepto
274 agocytic function, and surface expression of granulocyte-macrophage colony-stimulating factor recepto
275 76] RFU/cell; P < 0.0001); and expression of granulocyte-macrophage colony-stimulating factor recepto
276 ession and function of circulating leukocyte granulocyte-macrophage colony-stimulating factor recepto
277 lveolar proteinosis without mutations in the granulocyte-macrophage colony-stimulating factor recepto
278 ith LNK deficiency to increase interleukin 3/granulocyte-macrophage colony-stimulating factor recepto
279 na propria DCs under the control of Flt3 and granulocyte-macrophage-colony-stimulating factor recepto
280 Granulocyte-macrophage colony-stimulating factor-recepto
281 Granulocyte-macrophage colony-stimulating factor-recepto
282 s were isolated and expression of CSF2RB and granulocyte-macrophage colony-stimulating factor-respons
283 in granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor resulte
284 of intestinal lamina propria leukocytes with granulocyte-macrophage colony-stimulating factor resulte
285 r PMNs exposed in vitro to recombinant human granulocyte-macrophage colony stimulating factor (rhGM-C
287 cells are a recently described population of granulocyte macrophage colony-stimulating factor-secreti
288 n combination with an allogeneic, cell-based granulocyte-macrophage colony-stimulating factor-secreti
289 cal models have demonstrated the efficacy of granulocyte-macrophage colony-stimulating factor-secreti
290 ed of autologous leukemia cells admixed with granulocyte-macrophage colony-stimulating factor-secreti
291 GVAX pancreas, granulocyte-macrophage colony-stimulating factor-secreti
292 Furthermore, bone marrow cells cultured in granulocyte macrophage colony-stimulating factor show ac
293 /6 background does not induce hyperactivated granulocyte macrophage colony-stimulating factor signali
294 E2; this apotope, in a setting that includes granulocyte macrophage colony-stimulating factor-stimula
295 that included the immunomodulatory adjuvants granulocyte-macrophage colony-stimulating factor, Toll-l
296 In a randomized phase II trial, granulocyte-macrophage colony stimulating factor treatme
298 of granulocyte colony-stimulating factor and granulocyte macrophage colony-stimulating factor when in
299 nts with osteosarcoma who were given inhaled granulocyte-macrophage colony-stimulating factor with fi
300 ce of myeloid progenitor hypersensitivity to granulocyte-macrophage colony-stimulating factor with my
WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。